Actavis to Enter Biosimilars

Generic pharmaceuticals producer Actavis (Hafnarfjordur, Iceland) says it plans to enter the field of biosimilars. Actavis has entered into an initial agreement with biotechnology company Bioton (Warsaw) to facilitate discussions for possibly entering into an agreement to acquire 51% stake in Biopartners (Baar, Switzerland), a unit of Bioton. Actavis will perform a due diligence of Biopartners. Financial terms have not yet been agreed. “By entering into biosimilars the generic companies gain access to a portfolio that requires a new approach to development...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers